The present invention is about a pharmaceutical composition, an oral preparation, and an injection preparation containing a G protein-coupled Receptor19 (GPCR19) agonist, specifically sodium taurodeoxycholate(HY2191) and its derivative, as an active ingredient for preventing or treating allergic skin diseases. The present invention is also about an external preparation and a cosmetic composition containing said pharmaceutical composition for preventing and improving allergic skin diseases. The said pharmaceutical composition shows an excellent efficacy in treating and improving allergic dermatitis compared with the steroid ointments or immunosuppressive ointments currently used. The said pharmaceutical composition reduces the level of serum IgE, which is a major factor causing allergic dermatitis, increases TH1 cytokine alleviating allergic dermatitis and reduces TH2 cytokine that exacerbates allergic dermatitis. The said pharmaceutical composition also reduces infiltration of a mast cell, eosinophil, and neutrophil in dermis and ameliorates clinical symptoms such as erythema, hemorrhage, edema, excoriation, erosion, scaling and dryness. Thus, the said pharmaceutical composition can be used to prevent and treat allergic skin diseases.

The present invention is about a pharmaceutical composition, an oral preparation, and an injection preparation containing a G protein-coupled Receptor19 (GPCR19) agonist, specifically sodium taurodeoxycholate(HY2191) and its derivative, as an active ingredient for preventing or treating allergic skin diseases. The present invention is also about an external preparation and a cosmetic composition containing said pharmaceutical composition for preventing and improving allergic skin diseases. The said pharmaceutical composition shows an excellent efficacy in treating and improving allergic dermatitis compared with the steroid ointments or immunosuppressive ointments currently used. The said pharmaceutical composition reduces the level of serum IgE, which is a major factor causing allergic dermatitis, increases TH1 cytokine alleviating allergic dermatitis and reduces TH2 cytokine that exacerbates allergic dermatitis. The said pharmaceutical composition also reduces infiltration of a mast cell, eosinophil, and neutrophil in dermis and ameliorates clinical symptoms such as erythema, hemorrhage, edema, excoriation, erosion, scaling and dryness. Thus, the said pharmaceutical composition can be used to prevent and treat allergic skin diseases.

A water-soluble cleaning agent sheet includes the following components in parts by weight: 12-35 parts of film-forming agent, 0-3 parts of thickening agent, 0-10 parts of water softener, 15-50 parts of anionic surfactant, 1-10 parts of non-ionic surfactant, 1-10 parts of amphiprotic surfactant, 0-10 parts of solubilizer, 1-10 parts of acrylate polymer; 0-10 parts of plant extract, and 0-1 parts of preservative.

A process comprising at least the steps of: (a) preparing a first mixture comprising at least one non-polar organic solvent, at least one first polar organic solvent and a catalyst, (b) preparing a second mixture comprising at least one of: C7 to C25 carboxylic acids, optionally alkyl benzene sulfonic acids and C2 to C6 carboxylic acids, (c) adding an amount of a calcium base to the first mixture to obtain a third mixture, (d) adding the second mixture of acids of step (b) to the third mixture of step (c) to obtain a fourth mixture; and carbonating the fourth mixture of step (d) by adding therein a given amount of an organic carbonate, wherein in step (c), the added amount of the calcium base allows neutralization of the carboxylic acids in step (d) and forms water as a neutralization product. The process is free of carbon dioxide injection for carbonation.

A process comprising at least the steps of: (a) preparing a first mixture comprising at least one non-polar organic solvent, at least one first polar organic solvent and a catalyst, (b) preparing a second mixture comprising at least one of: C7 to C25 carboxylic acids, optionally alkyl benzene sulfonic acids and C2 to C6 carboxylic acids, (c) adding an amount of a calcium base to the first mixture to obtain a third mixture, (d) adding the second mixture of acids of step (b) to the third mixture of step (c) to obtain a fourth mixture; and carbonating the fourth mixture of step (d) by adding therein a given amount of an organic carbonate, wherein in step (c), the added amount of the calcium base allows neutralization of the carboxylic acids in step (d) and forms water as a neutralization product. The process is free of carbon dioxide injection for carbonation.